27 results
Thumbnail

D1.149 - Murine IgG1 increased y subcutaneous immunotherapy suppressed development of allergic asthma

Thumbnail

D1.150 - Study design for the saFety assessment of an Accelerated up-dosing scheme using one Strength of a native house dust mite allergen extract for subcutaneous immunoTherapy in children with allergic asthma in China (FAST II study)

Thumbnail

D1.152 - Incidence of patients who needed to change their allergy immunotherapy product specific to mites or pollens in Spanish allergy unitsIncidence of switching specific allergic immunotherapy products in Spanish allergy units

Thumbnail

D1.153 - Protocol for a randomized, 5-arm study to evaluate the combination of omalizumab and allergen immunotherapy in patients with asthma due to house dust mites

Thumbnail

D1.154 - Safety of ultra-rush immunotherapy starting protocol with the molecular extract Diater Alt a 1 mol mix

Thumbnail

D1.155 - Alterations in B cell memory induced by house dust mite allergen immunotherapy

Thumbnail

D1.156 - Early Immunologic Parameters Predicting Response to Sublingual Immunotherapy in Allergic Rhinitis Patients

Thumbnail

D1.157 - Type II Cytokine-Mediated Regulation of Alarmin Receptors in B Cells: Implications for Eosinophilic Esophagitis

Thumbnail

D1.159 - The successful resolve of nasal polyps in patient with dupilumab treatment

Thumbnail

D1.309 - Association of Antenatal Corticosteroids with Risk of Autoimmune Diseases in Children: a Nationwide Cohort Study

Thumbnail

D1.308 - Case report: challenges in a long-term prophylaxis in hereditary angioedema (HAE)

Thumbnail

D1.310 - Phenotypes of patients with Hereditary Angioedema (HAE): a case series

Thumbnail

D1.311 - Treatment Dilemmas in CARMIL2 Deficiency

Thumbnail

D1.312 - Acquired C1-inhibitor deficiency angioedema treated with lanadelumab: a case series

Thumbnail

D1.313 - Inborn Error of Immunity Associated Inflammatory Bowel Disease at a Tertiary Care Center

Thumbnail

D1.315 - Classifying the unclassifiable: diagnosis, characterization, and management of adults with unclassified primary antibody deficiency (unPAD)

Thumbnail

D1.316 - Lessons Learned from the Diagnosis and Management of a female pediatric patient with NCF2 Mutations and Chronic Granulomatous Disease

Thumbnail

D1.317 - A Retrospective Analysis of Dengue-Associated Hemophagocytic Lymphohistiocytosis in a Dengue-Endemic Country

Thumbnail

D1.318 - Extending Lanadelumab Dosing Intervals to Every 4 Weeks With Sustained Effectiveness for Hereditary Angioedema Attack Prevention: An Analysis From the Final ENABLE Study Data

Thumbnail

D1.319 - The Silent Threat of Hereditary Angioedema in Children: Single Center Experience